Sector Brief - March 20, 2024
Outsourced Pharma Services & Pharma Tech
Biopharmaceutical companies increasingly rely on technology and service vendors to accelerate R&D and time to market as well as optimize the commercial success of therapies. These companies seek to optimize every portion of the development and commercialization life cycle, creating M&A opportunities for outsourced pharma services and pharma technology. In this Q1 sector brief from our Healthcare & Life Sciences Group and Technology Group, we share insights in the space, including legacy commercialization approaches, solutions that enhance supply chain visibility, drivers of tech implementation, and a focus on real-world evidence and data.
Learn more about M&A trends in this sector.
Contacts
Paul Hepper
Managing Director
Healthcare & Life Sciences
Dan Linsalata
Managing Director
Technology
Additional Contacts
Dr. Julian Feneley
Managing Director
Healthcare & Life Sciences
Stephan Döring
Director
Healthcare & Life Sciences
Andrey Dvorkin
Director
Healthcare & Life Sciences
Rob Crampton
Vice President
Healthcare & Life Sciences